{'fraction_non_alphanumeric': 0.024017467248908297, 'fraction_numerical': 0.004366812227074236, 'mean_word_length': 5.464788732394366, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Combined therapy with tetrabenazine and pimozide in Huntington's chorea: pilot study.

Current medication for Huntingtons chorea is based on compounds which affect the activity of acetylcholine and dopamine in the basal ganglia and is unsatisfactory. This report describes a small clinical trial of dopamine antagonists, tetrabenazine (Nitoman) and pimozide (Orap). Improvement was early and striking but was not maintained over the trial period of 83 weeks.